IPP Bureau
Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr
By IPP Bureau - February 02, 2024
Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023
Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr
By IPP Bureau - February 02, 2024
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr
By IPP Bureau - February 02, 2024
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories reports Q3 FY24 consolidated PAT at Rs. 31.99 Cr
By IPP Bureau - February 02, 2024
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24
By IPP Bureau - February 01, 2024
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Glenmark partners Pfizer to launch Abrocitinib in India
By IPP Bureau - February 01, 2024
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Zydus Lifesciences launches Rexigo
By IPP Bureau - February 01, 2024
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Orchid Pharma's Exblifeb granted EMA approval
By IPP Bureau - February 01, 2024
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Sun Pharmaceutical Industries Q3 FY24 consolidated PAT up at Rs. 2,560.54 Cr
By IPP Bureau - February 01, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study
By IPP Bureau - January 31, 2024
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
By IPP Bureau - January 31, 2024
Submission to be reviewed under FDA real-time oncology review and Project Orbis
100 bedded Yoga & Naturopathy Hospital to come up in Dibrugarh
By IPP Bureau - January 30, 2024
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
Ascletis announces dosing of the first patient in Phase III clinical trial of ASC40
By IPP Bureau - January 30, 2024
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment
By IPP Bureau - January 30, 2024
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
